Bo Zheng, Yong Huo, Stephen W-L Lee, Jitendra P S Sawhney, Hyo-Soo Kim, Rungroj Krittayaphong, Stuart J Pocock, Vo T Nhan, Angeles Alonso Garcia, Chee Tang Chin, Jie Jiang, Stephen Jan, Ana Maria Vega, Nobuya Hayashi, Tiong K Ong
BACKGROUND: Despite guideline recommendations, dual antiplatelet therapy (DAPT) is frequently used for longer than 1 year after an acute coronary syndrome (ACS) event. In Asia, information on antithrombotic management patterns (AMPs), including DAPT post discharge, is sparse. This analysis evaluated real-world AMPs up to 2 years post discharge for ACS. HYPOTHESIS: There is wide variability in AMP use for ACS management in Asia. METHODS: EPICOR Asia (NCT01361386) is a prospective observational study of patients discharged after hospitalization for an ACS in eight countries/regions in Asia, followed up for 2 years...
July 2, 2020: Clinical Cardiology